CCL2 may serve as well as a predictive biomarker for patients with prostate cancer treated with ADT (Figure 4D), suggesting that ADT alone might not be sufficient for patients with prostate cancer with higher CCL2 levels. The gene discussed is CCL2; the disease is prostate cancer.